Highly active antiretroviral therapy alters inflammation linked to platelet cytokines in HIV-1-infected patients

Journal of Infectious Diseases

Volumn 208, Issue 5, 2013, Pages 868-870

  Damien, Pauline ^a   Cognasse, Fabrice ^a,b   Lucht, Frédéric ^a,c   Suy, Florence ^c   Pozzetto, Bruno ^a   Garraud, Olivier ^a,b,d   Hamzeh Cognasse, Hind ^a  

^a UNIVERSITÉ DE LYON   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^d UNIVERSITÉ JEAN MONNET   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD40 LIGAND; CYTOKINE; GROWTH REGULATED ONCOGENE ALPHA PROTEIN; PADGEM PROTEIN; RANTES; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG RESPONSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFLAMMATION; LETTER; NONHUMAN; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; TREATMENT DURATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD PLATELETS; CYTOKINES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED;

EID: 84881633622     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit260     Document Type: Letter

References (10)

1. Hatano H, Jain V, Hunt PW, et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis 2013; 208:50-6.
2. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. TrendsMicrobiol 2012; 21:6-13.
3. Donhauser N, Pritschet K, Helm M, et al. Chronic immune activation in HIV-1 infection contributes to reduced interferon alpha production via enhanced CD40:CD40 ligand interaction. PLoS One 2012; 7:e33925.
4. Naranbhai V, Abdool Karim SS, Altfeld M, et al. Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis 2012; 206:993-1001.
5. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002; 106:896-9.
6. Cognasse F, Hamzeh-Cognasse H, Berthet J, et al. Altered release of regulated upon activation, normal T-cell expressed and secreted protein from human, normal platelets: contribution of distinct HIV-1MN gp41 peptides. AIDS 2009; 23:2057-9.
7. Landro L, Ueland T, Otterdal K, Froland SS, Aukrust P. Persistently raised plasma levels of platelet-derived inflammatory mediators in HIV-infected patients during highly active antiretroviral therapy. J Thromb Haemost 2011; 9:1075-7.
8. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011; 11:264-74.
9. Aukrust P, Muller F, Lien E, et al. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis 1999; 179: 74-82.
10. Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface Pselectin but continue to circulate and function. Proc Natl Acad Sci USA 1996; 93: 11877-82.